[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neurocognitive-disorders-mild\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neurocognitive-disorders-mild":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,52,85],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":34,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100614447","phase-2-fisetin-in-mild-alzheimers-disease-100614447",false,"NCT07279714","Fisetin in Mild Alzheimer's Disease","Fisetin Intervention Study in Mild Alzheimer's Disease","FIS-AD","Inclusion Criteria:\n\n* Mild cognitive impairment due to Alzheimer's disease OR mild Alzheimer Dementia\n* Moca score of 11 or higher\n* Stable psychotropics and cognitive enhancing medications\n\nExclusion Criteria:\n\n* Known hypersensitivity or allergy to fisetin\n* Presence of any medical condition, or abnormal routine blood test, that the investigator believes would put the subject at risk or would preclude the patient from completing all aspects of the trial\n* Unstable medical disorders\n* Ongoing treatment for active infection with antibiotics\u002Fantifungals\n* Ongoing treatment for cancer\n* Active alcohol or substance use disorder\n* Recent active bleeding\n* Patients taking oral anticoagulants, anti-cancer, anti-seizure medications, or other medications that could have a significant interaction with fisetin\n* Use within the last month of other senolytic supplements, antioxidant supplements, natural health products\n* Other neurologic or neurodegenerative conditions impacting cognition\n* Active Major Depressive Episode, active suicidal thoughts or psychosis\n* Any thing that would preclude the ability to undergo an MRI scan","ALL","60 Years",{"count":20,"type":21},5,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This pilot study will evaluate the safety and tolerability of the natural health product, fisetin, in older adults with mild cognitive impairment or mild Alzheimer's disease dementia.",[27,28,29,30,31,32,33],"Alzheimer s Disease","Alzheimer Dementia","Alzheimer Dementia (AD)","Alzheimer Disease","Mild Cognitive Disorder","Neurocognitive Disorders, Mild","Neurocognitive Disorder",[35,36,37,38],"fisetin","alzheimer's disease","safety","tolerability","RECRUITING","2026-04-10",{"date":42,"type":43},"2026-04-13","ACTUAL",{"date":45,"type":43},"2026-01-27",{"date":47,"type":21},"2026-11",{"name":49,"class":50},"Sunnybrook Health Sciences Centre","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":22,"phases":64,"briefSummary":66,"conditions":67,"keywords":70,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":51},"100474424","modulating-neurocognitive-processes-of-learning-to-trust-and-distrust-in-aging-100474424","NCT05457725","Modulating Neurocognitive Processes of Learning to Trust and Distrust in Aging","Characterizing and Modulating Neurocognitive Processes of Learning to Trust and Distrust in Aging II","DecidingBrain","Inclusion Criteria:\n\n* Able to provide verbal and written informed consent\n* Fluent English speaker\n* At least 8th grade education\n* On stable medication regimen\n\nExclusion Criteria:\n\n* Pregnancy\n* Magnetic resonance imaging contraindications (e.g., certain metallic objects in body, claustrophobia)\n* Current major depression defined as scores \\>14 on the Beck Depression Inventory-II\n* Impaired scores on the Telephone Interview for Cognitive Status (TICS; cut-off of \\>30)\n* Current use of medications with significant anticholinergic properties due to potential influence on memory (\"memory enhancing\"; e.g., Aricept or Namenda)\n* Current use of anticonvulsant, neuroleptic, sedatives, or other medications known to affect cognition\n* Uncorrected visual and hearing impairments\n* Neurologic conditions affecting the brain (e.g., severe stroke, epilepsy, traumatic brain injury with \\>30-minute loss of consciousness)\n* Impaired scores on a cognitive screening measure, the Montreal Cognitive Assessment (MoCA); for older adults the cutoff will be age and education corrected\n* Unstable medical illness (e.g., metastatic cancer)\n* Significant cardiovascular conditions (e.g., major heart attack)\n* Will not exclude participants who are taking anti-depressant medications. Use of antidepressants (particularly SSRI's) and anxiolytic medications will be recorded and included in post-hoc analyses","18 Years","100 Years",{"count":63,"type":21},68,[65],"NA","Much of human interaction is based on trust. Aging has been associated with deficits in trust-related decision making, likely further exacerbated in age-associated neurodegenerative disease (Alzheimer's disease\u002FAD), possibly underlying the dramatically growing public health problem of elder fraud. Optimal trust-related decision making and avoiding exploitation require the ability to learn about the trustworthiness of social partners across multiple interactions, but the role that learning plays in determining age deficits in trust decisions is currently unknown.\n\nAim: Probe the malleability of the underlying neurocircuitry of trust-learning deficits in aging. This study will utilize real-time fMRI neurofeedback to train older adults in brain activity up-regulation toward enhanced trust-related learning in aging and confirm critical mechanisms of experience-dependent social decisions in aging.\n\nGrant R01AG072658 Aim 3: Test the malleability of trust-learning neurocircuitry toward optimized trust-related decision making in aging.",[68,69,32],"Aging","Cognitive Change",[71,72,73,74,75],"Decision Making","Trust","Learning","Socioemotional","Vulnerability to Exploitation","2026-04-03",{"date":78,"type":43},"2026-04-06",{"date":80,"type":43},"2024-10-08",{"date":82,"type":21},"2027-04-30",{"name":84,"class":50},"University of Florida",{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":94,"phases":4,"briefSummary":95,"conditions":96,"keywords":101,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":20},"100611163","effects-of-personalized-digital-reminiscence-therapy-on-patients-with-neurocognitive-disorders-100611163","NCT07237009","Effects of Personalized Digital Reminiscence Therapy on Patients With Neurocognitive Disorders","Effects of Personalized Reminiscence Sessions Delivered by a Digital Conversational Agent to Patients With Neurocognitive Disorders","Inclusion Criteria:\n\n* Men and women over 60 years of age.\n* DSM-5 diagnosis: Early stage of major neurocognitive disorders or MCI (Mild Cognitive Impairment) including all underlying causes.\n* Have a Mini-Mental State Exam score of 21 ≤ MMSE ≤ 28.\n* Presence of mild or moderate depression, or presence of mild or moderate apathy, or presence of both\n* Displays the necessary physical and cognitive abilities, without major limitations compromising interaction with the digital tool.\n* Having voluntarily and informedly agreed to participate in the study (signed written consent).\n* Subject's ability to hear and see the digital tool's stimuli (tests integrated into the tool).\n* Patients with access to an Apple device (smartphone or tablet), either personal or provided by the sponsor, running iOS version 16 or higher, with internet access.\n* Patient has at least one close referent who declares their wish to contribute to the collection of biographical information via the digital messaging group.\n* Subjects covered by a social security scheme.\n\nExclusion Criteria:\n\n* Patients with moderate or severe dementia (MMSE score ≤ 20) because implicit memory recall is less effective in moderate or severe stages for people with PWD.\n* Presence of major psychiatric disorders (e.g., schizophrenia, severe major depressive episode, bipolar disorder).\n* Major hearing or visual impairments.\n* History of premorbid intellectual disability.\n* Patients under guardianship, conservatorship, or legal protection.\n* Patients who have already used the Lilia app\n* Participating simultaneously in another study involving human subjects, a clinical investigation, or a therapeutic trial for the entire duration of the study.\n* Patients who have received a new treatment related to neurocognitive disorders (medication) during the 3 months prior to the inclusion visit.",{"count":93,"type":21},80,"OBSERVATIONAL","This study aims to observe the effects of daily personalized digital reminiscence sessions, conducted with the help of a digital conversational agent, and to determine whether these sessions lead to improvements in symptoms such as apathy and depression.\n\nThe researchers therefore seek to observe whether this daily use can improve certain aspects of well-being, such as motivation, mood, sleep quality, quality of life, and engagement with the tool.\n\nThe study also aims to assess whether simple reminders delivered via the application are sufficient to encourage regular use without external assistance.\n\nParticipants will:\n\n* Use the reminiscence app for 25 days for 10-15 minutes.\n* Have a primary caregiver help personalize the app by sharing family memories, other relatives may optionally contribute in a private group.\n* Complete brief questionnaires at the start and during follow-up routine visits (for example, apathy and depression scales, sleep, and quality of life).",[32,97,98,99,100],"Cognitive Impairment, Mild","Depression Mild","Apathy","Apathy in Dementia",[102,103,99,104,105,106],"Mild Cognitive Impairment","Dementia","Mild Depression","Digital Reminiscence therapy","personalized Reminiscence therapy","2026-03-06",{"date":109,"type":43},"2026-03-09",{"date":111,"type":43},"2025-10-14",{"date":113,"type":21},"2026-12",{"name":115,"class":116},"KompanionCare SAS","INDUSTRY"]